Brenda Maria Rosales

Brenda Maria Rosales

Auto-generated profile, based on publicly available information

Brenda Maria Rosales

School of Public Health, Faculty of Medicine and Health, The University of Sydney Sydney New South Wales Australia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
BRBrenda M. Rosales
Brenda M. Rosales
NMNicole De La Mata
Nicole De La Mata
CVClaire Vajdic
Claire Vajdic
PKPatrick J. Kelly
Patrick J. Kelly
KWKate Wyburn
Kate Wyburn
AWAngela C. Webster
Angela C. Webster

16 November 2021 in BMJ
Verified
Journal Article
Open access
PDF file
NMNicole L De La Mata
Nicole L De La Mata
BRBrenda Rosales
Brenda Rosales
GMGrace MacLeod
Grace MacLeod
PKPatrick J Kelly
Patrick J Kelly
PMPhilip Masson
Philip Masson
AWAngela C Webster
Angela C Webster
Objective To evaluate sex differences in mortality among people with kidney failure compared with the general population. Design Population based cohort study using data linkage. Setting The Australian and New Zealand Dialysis and Transplant Registry (ANZDATA), which includes all patients receiving kidney replacement therapy in Australia (1980-2019) and New Zealand (1988-2019). Data were linked to national death registers to determine deaths and their causes, with additional details obtained from ANZDATA. Participants Of 82 844 people with kidney failure, 33 329 were female (40%) and 49 555 were male (60%); 49 376 deaths (20 099 in female patients; 29 277 in male patients) were recorded over a total of 536 602 person years of follow-up. Main outcome measures Relative measures of survival, including standardised mortality ratios, relative survival, and years of life lost, using general population data to account for background mortality (adjusting for country, age, sex, and year). Estimates were stratified by dialysis modality (haemodialysis or peritoneal dialysis) and for the subpopulation of kidney transplant recipients. Results Few differences in outcomes were found between male and female patients with kidney failure. However, compared with the general population, female patients with kidney failure had greater excess all cause deaths than male patients (female patients: standardised mortality ratio 11.3, 95% confidence interval 11.2 to 11.5, expected deaths 1781, observed deaths 20 099; male patients: 6.9, 6.8 to 6.9, expected deaths 4272, observed deaths 29 277). The greatest difference was observed among younger patients and those who died from cardiovascular disease. Relative survival was also consistently lower in female patients, with adjusted excess mortality 11% higher (95% confidence interval 8% to 13%). Average years of life lost was 3.6 years (95% confidence interval 3.6 to 3.7) greater in female patients with kidney failure compared with male patients across all ages. No major differences were found in mortality by sex for haemodialysis or peritoneal dialysis. Kidney transplantation reduced but did not entirely remove the sex difference in excess mortality, with similar relative survival (P=0.83) and years of life lost difference reduced to 2.3 years (95% confidence interval 2.2 to 2.3) between female and male patients. Conclusions Compared with the general population, female patients had greater excess deaths, worse relative survival, and more years of life lost than male patients, however kidney transplantation reduced these differences. Future research should investigate whether systematic differences exist in access to care and possible strategies to mitigate excess mortality among female patients.

26 October 2020 in JMIR Research Protocols
Verified
Journal Article
Open access
BRBrenda Rosales
Brenda Rosales
JHJames Hedley
James Hedley
NMNicole De La Mata
Nicole De La Mata
CVClaire Vajdic
Claire Vajdic
PKPatrick Kelly
Patrick Kelly
TGThe SAFEBOD Study Group
The SAFEBOD Study Group
Background: Tension lies between the need to increase access to organ transplantation and the equally urgent need to prevent inadvertent transmission of infectious diseases or cancer from organ donors. Biovigilance, or the evaluation of potential donors, is often time-pressured and may be based on incomplete information. Objective: The Safety and Biovigilance in Organ Donation (SAFEBOD) study aims to improve estimates of infection and cancer transmission risk and explore how real-time data access could support decision-making. Methods: We will link existing donor referral, actual donor, recipient, and health-outcome data sets from 2000-2015 in New South Wales. Organ donor data sets will include the Organ Donor Characterizing Risk-Profile of Donors Study, the National Organ Matching System, the Australian and New Zealand Organ Donor Register, and the Australian and New Zealand Living Donor Kidney Register. Recipient data sets will include the Australian and New Zealand Dialysis and Transplant Register, the Australian and New Zealand Cardiothoracic Register, the Australian and New Zealand Islet and Pancreas Register, and the Australian and New Zealand Liver Transplant Register. New South Wales health outcome data sets will include HIV and AIDS Notifications and Surveillance Data, the Notifiable Conditions Information Management System, Admitted Patient Data Collection, Emergency Department Data Collection, the Central Cancer Registry, and the Cause of Death Data Collection. We will link organ donors to transplant recipients and health outcomes data sets using probabilistic data-matching based on personal identifiers. Transmission and nontransmission events will be determined by comparing previous cases in donors and posttransplant cases in recipients. We will compare the perceived-risk at referral with the verified risk from linked health outcome data sets and the odds of cancer or contracting an infectious disease in organ recipients from donors based on their transmission-risk profile and estimate recipient survival by donor transmission risk group. Results: Data were requested from each of the listed registries in September 2018, and data collection is ongoing. Linked data from all listed data sets are expected to be complete in September 2020. Conclusions: The SAFEBOD study will overcome current limitations in organ donation by accessing comprehensive information on referred organ donors and recipients in existing data sets. The study will provide robust estimates of disease transmission and nontransmission events based on recent data. It will also describe the agreement between perceived risk estimated at the time of referral and verified risk when all health outcome data are accessible. The improved understanding of transmission and nontransmission events will inform clinical decisions and highlight where current policies can be revised to broaden the acceptance of deceased donors. International Registered Report Identifier (IRRID): DERR1-10.2196/18282

30 April 2022 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
BRBrenda M. Rosales
Brenda M. Rosales
NMNicole De La Mata
Nicole De La Mata
CVClaire M. Vajdic
Claire M. Vajdic
PKPatrick J. Kelly
Patrick J. Kelly
KWKate Wyburn
Kate Wyburn
AWAngela C. Webster
Angela C. Webster

1 April 2019 in Transplantation Direct
Verified
Journal Article
Open access
BRBrenda Maria Rosales
Brenda Maria Rosales
JLJulian Langton-Lockton
Julian Langton-Lockton
ACAlyssa M. Cornall
Alyssa M. Cornall
JRJennifer M. Roberts
Jennifer M. Roberts
RHRichard J. Hillman
Richard J. Hillman
AWAngela Claire Webster
Angela Claire Webster
Kidney recipients have anal cancer rates 3 times higher than the general population in Australia and New Zealand. High-risk human papillomavirus (HPV) genotypes are implicated in the majority of anal cancers. Establishing the epidemiology of anal HPV infection and precursors of anal cancer in transplant recipient populations is 1 consideration in any potential screening program. The Transplant and Anal Neoplasia Study is a cross-sectional study of the prevalence of anal cytological abnormalities and HPV deoxyribonucleic acid in kidney transplant recipients, as well as evaluating the acceptability of an anal cancer screening intervention. The study aims to recruit 100 kidney transplant recipients, older than 18 years, in Australia. Transplant recipients attending for a protocol biopsy at 3 and 12 months and annually posttransplant are approached to participate. Participants undergo an anal swab, which is then analyzed using liquid-based cytological examination and tested for the detection of 37 anogenital HPV deoxyribonucleic acid genotypes. Participants also complete a demographic and behavioral questionnaire that covers sexual behavior, history of anal symptoms, and possible anal cancer risk factors. Associations will be tested using multiple regression analysis. Recruitment for the study began in 2015 and is ongoing. To date, 96 (77%) of 125 kidney transplant recipients approached have consented to the study. The mean age is 48 (median, 47 y; range, 20–76 y), 59% are male, and Northwest European (58%) represented the largest ethnic group. No participants self-identified as Aboriginal or Torres Strait Islander. High consent rates and positive qualitative results suggest that a larger screening program may be well received by kidney transplant recipients, with increased resources and some modification to the timing of approach. Further results of the study will inform the possible implementation of a larger screening trial for prevention of anal cancers in kidney and other solid organ transplant recipients.

8 September 2021 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
BRBrenda M. Rosales
Brenda M. Rosales
JLJulian Langton‐Lockton
Julian Langton‐Lockton
JHJames Hedley
James Hedley
ACAlyssa M. Cornall
Alyssa M. Cornall
JRJennifer M. Roberts
Jennifer M. Roberts
TGthe Transplant and Anal Neoplasia Study group
the Transplant and Anal Neoplasia Study group